Cochrane · systematic review · CD005134
Pentasaccharides for the prevention of venous thromboembolism
Dong, K, Song, Y, Li, X, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
42
current version
GRADE rated
41
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 2.4%Very low 20 · 47.6%Low 8 · 19%Moderate 10 · 23.8%High 3 · 7.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Fondaparinux versus placebo for the prevention of venous thromboembolism
Population: people requiring prevention of venous thromboembolism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total VTE Fondaparinux vs placebo | RR 0.24 [0.15, 0.38] | 8 studies · 5717 participants | Moderate Downgraded: inconsistency, publication bias |
Symptomatic VTE Fondaparinux vs placebo | RR 0.15 [0.06, 0.36] | 8 studies · 6503 participants | High |
Total DVT Fondaparinux vs placebo | RR 0.25 [0.15, 0.4] | 8 studies · 5715 participants | Moderate Downgraded: inconsistency, publication bias |
Proximal DVT Fondaparinux vs placebo | RR 0.12 [0.04, 0.39] | 7 studies · 2746 participants | Moderate Downgraded: imprecision, inconsistency, publication bias |
Total PE Fondaparinux vs placebo | RR 0.16 [0.04, 0.62] | 8 studies · 6412 participants | High |
Major bleeding Fondaparinux vs placebo | RR 2.56 [1.48, 4.44] | 8 studies · 6659 participants | Moderate Downgraded: imprecision, publication bias |
All causes of death Fondaparinux vs placebo | RR 0.76 [0.48, 1.22] | 8 studies · 6674 participants | Moderate Downgraded: imprecision, publication bias |
Fondaparinux versus LMWH for the prevention of venous thromboembolism
Population: people requiring prevention of venous thromboembolism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total VTE Fondaparinux vs LMWH | RR 0.55 [0.42, 0.73] | 11 studies · 9339 participants | Moderate Downgraded: inconsistency, publication bias |
Symptomatic VTE Fondaparinux vs LMWH | RR 1.03 [0.65, 1.63] | 9 studies · 12240 participants | Moderate Downgraded: imprecision, publication bias |
Total DVT Fondaparinux vs LMWH | RR 0.54 [0.4, 0.71] | 10 studies · 9356 participants | Moderate Downgraded: inconsistency, publication bias |
Proximal DVT Fondaparinux vs LMWH | RR 0.58 [0.33, 1.02] | 9 studies · 8361 participants | Low Downgraded: imprecision, inconsistency, publication bias |
Total PE Fondaparinux vs LMWH | RR 1.24 [0.65, 2.34] | 10 studies · 12350 participants | Moderate Downgraded: imprecision, publication bias |
Major bleeding Fondaparinux vs LMWH | RR 1.38 [1.09, 1.75] | 11 studies · 12501 participants | High |
All causes of death Fondaparinux vs LMWH | RR 0.88 [0.63, 1.22] | 11 studies · 12400 participants | Moderate Downgraded: imprecision, publication bias |
Fondaparinux versus variable dose warfarin for the prevention of venous thromboembolism
Population: patients requiring prevention of venous thromboembolism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total VTE Fondaparinux vs variable dose warfarin | no estimate extracted | 1 study · 236 participants | Very low Downgraded: imprecision |
Symptomatic VTE Fondaparinux vs variable dose warfarin | no estimate extracted | 1 study · 236 participants | Very low Downgraded: imprecision |
Total DVT Fondaparinux vs variable dose warfarin | no estimate extracted | 1 study · 236 participants | Very low Downgraded: imprecision |
Proximal DVT Fondaparinux vs variable dose warfarin | no estimate extracted | 1 study · 236 participants | Very low Downgraded: imprecision |
Total PE Fondaparinux vs variable dose warfarin | no estimate extracted | 1 study · 236 participants | Very low Downgraded: imprecision |
Major bleeding Fondaparinux vs variable dose warfarin | RR 7 [0.37, 134.05] | 1 study · 236 participants | Very low Downgraded: imprecision |
All causes of death Fondaparinux vs variable dose warfarin | no estimate extracted | 1 study · 236 participants | Very low Downgraded: imprecision |
Fondaparinux versus 1 mg warfarin for the prevention of venous thromboembolism
Population: people requiring prevention of venous thromboembolism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total VTE Fondaparinux vs 1 mg warfarin | RR 0.2 [0.01, 4.12] | 1 study · 236 participants | Very low Downgraded: imprecision |
Symptomatic VTE Fondaparinux vs 1 mg warfarin | no estimate extracted | 1 study · 236 participants | Very low Downgraded: imprecision |
Total DVT Fondaparinux vs 1 mg warfarin | RR 0.2 [0.01, 4.12] | 1 study · 236 participants | Very low Downgraded: imprecision |
Proximal DVT Fondaparinux vs 1 mg warfarin | no estimate extracted | 1 study · 236 participants | Very low Downgraded: imprecision |
Total PE Fondaparinux vs 1 mg warfarin | no estimate extracted | 1 study · 236 participants | Very low Downgraded: imprecision |
Major bleeding Fondaparinux vs 1 mg warfarin | RR 3 [0.32, 28.43] | 1 study · 236 participants | Very low Downgraded: imprecision |
All causes of death Fondaparinux vs 1 mg warfarin | no estimate extracted | 1 study · 236 participants | Very low Downgraded: imprecision |
Fondaparinux versus edoxaban for the prevention of venous thromboembolism
Population: people requiring prevention of venous thromboembolism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total VTE Fondaparinux vs edoxaban | no estimate extracted | 1 study · 38 participants | Very low Downgraded: imprecision |
Symptomatic VTE Fondaparinux vs edoxaban | no estimate extracted | 1 study · 38 participants | Very low Downgraded: imprecision |
Total DVT Fondaparinux vs edoxaban | no estimate extracted | 1 study · 38 participants | Very low Downgraded: imprecision |
Proximal DVT Fondaparinux vs edoxaban | no estimate extracted | 1 study · 38 participants | Ungraded |
Total PE Fondaparinux vs edoxaban | no estimate extracted | 1 study · 38 participants | Very low Downgraded: imprecision |
Major bleeding Fondaparinux vs edoxaban | no estimate extracted | 1 study · 38 participants | Very low Downgraded: imprecision |
All causes of death Fondaparinux vs edoxaban | no estimate extracted | 1 study · 38 participants | Very low Downgraded: imprecision |
Fondaparinux versus mechanical thromboprophylaxis for the prevention of venous thromboembolism
Population: people requiring prevention of venous thromboembolism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total VTE Fondaparinux vs mechanical thromboprophylaxis | RR 0.61 [0.22, 1.67] | 1 study · 99 participants | Low Downgraded: imprecision |
Symptomatic VTE Fondaparinux vs mechanical thromboprophylaxis | no estimate extracted | 1 study · 120 participants | Low Downgraded: imprecision |
Total DVT Fondaparinux vs mechanical thromboprophylaxis | RR 0.63 [0.23, 1.72] | 1 study · 100 participants | Low Downgraded: imprecision |
Proximal DVT Fondaparinux vs mechanical thromboprophylaxis | no estimate extracted | 1 study · 105 participants | Low Downgraded: imprecision |
Total PE Fondaparinux vs mechanical thromboprophylaxis | no estimate extracted | 1 study · 120 participants | Low Downgraded: imprecision |
Major bleeding Fondaparinux vs mechanical thromboprophylaxis | no estimate extracted | 1 study · 120 participants | Low Downgraded: imprecision |
All causes of death Fondaparinux vs mechanical thromboprophylaxis | no estimate extracted | 1 study · 120 participants | Low Downgraded: imprecision |